Jared Kaltwasser

Clinical trials and targeted agents do not appear to affect health care–related quality of life, however.

A new case report highlights the difficulties in pinning down spinal muscular atrophy (SMA) when it presents in a mild form.

A new study highlights potential therapies to decrease cardiovascular risk in people with systemic lupus erythematosus (SLE) and identifies biomarkers that may indicate a heightened risk.

A patient who failed to respond to rituximab and steroids later saw dramatic improvement with sutimlimab

The research may eventually help clinicians optimize therapy with immune checkpoint inhibitors.

A new review article notes efforts to diagnose cholangiocarcinoma (CCA) early are hampered by a lack of biomarkers.

The technique outperformed physical examinations in identifying muscle fasciculations, which are common in spinal muscular atrophy (SMA).

A new study outlining the experiences of women with systemic lupus erythematosus (SLE) finds many women feel their initial symptoms are downplayed by providers, leading to costly delays in diagnosis.

Two studies showed how hospital-based trigger systems could help guide patients toward appropriate goals of care and in some cases palliative care.

Patients with cold agglutinin disease (CAD) had durable responses at week 53, and no new safety signals were reported.

New data suggest motor function improves with amifampridine.

A new review notes advances and remaining questions, and calls for better incorporation of data from veterans.

The tool could help clinicians better screen patients for adjuvant chemotherapy following curative resection for intrahepatic cholangiocarcinoma (ICC).

A new review article outlines current agreements and disagreements between association guidelines, but notes the recommendations are likely to change more in the future.

Data show surgery leads to the best outcomes.

Patients who received regular physical therapy had improvement that was 4 times better than nusinersen alone, findings from this new study show.

A booster dose of a SARS-CoV-2 vaccine cut infection risk nearly in half, study finds.

The analysis could help investigators better understand why a subset of patients with advanced melanoma develops resistance or does not respond to targeted therapy.

Better screenings and improved therapies have helped boost non–small cell lung cancer (NSCLC) outcomes, but investigators said some patient groups have seen less improvement than others.

This new report suggests patients with high-risk cutaneous squamous cell carcinoma (cSCC) have improved odds when they undergo Mohs micrographic surgery.

Veterans often have characteristics and comorbidities that can make them less likely to be included in clinical trials.

Over the past decade, the Veterans Health Administration (VHA) has sought to boost lung cancer screening rates, but several challenges remain.

New data show the types of malignancies, such as leukemias and myeloproliferative disorders, that are most common in children with Langerhans cell histiocytosis (LCH).

A narrative review shows that diagnosing systemic lupus erythematosus (SLE) requires physicians to keep an open and inquisitive mind.

Investigators note that the most recent systemic lupus erythematosus (SLE) classification system has quickly become the gold standard, but disease classification remains challenging.

A university hospital saw an initial drop of new cases, but treatment efficacy was unaffected.

The patient was 52 years old and underwent a liver transplant 13 years after his hematopoietic stem cell transplant (HSCT) to treat his sickle cell disease (SCD).

The tool relies on factors including creatinine, anti–double-stranded DNA antibody, and gender, among others.

Just 5% of patients in a cholangiocarcinoma cohort were categorized as microsatellite instability high (MSI-high), but those patients tended to have “excellent” responses to therapy.

Patients who received a diagnosis of small cell lung cancer (SCLC) between 2010 and 2016 had a nearly 2% increase in overall survival vs those who received their diagnosis between 2004 and 2010.